CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
CG Oncology (NASDAQ: CGON) said its CEO Arthur Kuan and President & COO Ambaw Bellete will present at the 44th Annual J.P.
Rhea-AI Summary
CG Oncology (NASDAQ: CGON) said its CEO Arthur Kuan and President & COO Ambaw Bellete will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 8:15 am PT / 11:15 am ET at the Westin St. Francis in San Francisco.
Investors can listen via a live audio webcast accessible from the company's Investor Relations website at www.cgoncology.com. A replay will be posted shortly after the presentation and archived for about 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CGON
On Jan 6, the day this news came out, CGON closed 0.82% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference edition
- 44th annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 15, 2026
- J.P. Morgan Healthcare Conference slot
- Presentation time PT
- 8:15 am PT
- Company presentation time
- Presentation time ET
- 11:15 am ET
- Company presentation time
- Webcast archive length
- 90 days
- Investor webcast replay availability
Historical Context
-
Announced second annual NMIBC research fellowship with two $50,000 grants.
-
Reported promising cretostimogene efficacy and tolerability in BOND-003 and CORE-008.
-
Added new director and noted initiation of BLA for cretostimogene.
-
Planned late-breaking SUO presentations and posters on cretostimogene trials.
-
Q3 2025 results, strong cash of $680.3M, BLA progress and Phase 3 enrollment.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California.
Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.